Ibrexafungerp Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg
Reference Brands: Brexafemme (USA)
Category:
Anti-fungal
Ibrexafungerp is a novel oral antifungal medication that works by inhibiting (1,3)-β-D-glucan synthase, an enzyme vital for fungal cell wall synthesis. Marketed as Brexafemme in the USA, it offers the first new oral antifungal class in over 20 years. It is primarily used to treat and prevent vulvovaginal candidiasis (yeast infections) caused by Candida species.
Ibrexafungerp is available in Tablets
and strengths such as 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ibrexafungerp is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ibrexafungerp can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing